(Alliance News) - Stock prices in London were mixed at midday on Friday as investors digested a weak GDP reading for the UK, a day after the Bank of England took the country's interest rates up to a 15-year-high. Read More
(Alliance News) - GSK PLC on Friday reported positive preliminary results from a phase 3 trial regarding its 5-in-1 meningococcal ABCWY vaccine candidate. Read More
(Alliance News) - GSK PLC on Friday welcomed a legal ruling in Canada that threw out a proposed class action made on behalf of users of a heartburn drug. Read More
(Alliance News) - Stocks in London were called to open higher on Friday, after data showed the UK economy expanded 0.1% over the first three months of the year. Read More
(Alliance News) - GSK PLC's respiratory syncytial virus vaccine Arexvy has "best-in-class potential" following its approval by the US Food & Drug Administration on Wednesday last week, according to analysts at Berenberg. Read More
(Alliance News) - Stocks in London were called to open lower on Thursday, amid a busy day for company earnings and an interest rate decision by the EU's central bank in the afternoon. Read More
GSK PLC - Brentford, London-based pharmaceutical firm - Announces the US Food & Drug Administration approves Arexvy, the world's first respiratory syncytial virus vaccine for older adults. States approval enables adults aged 60 years and older to be protected from RSV disease for the first time. Explains the approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease. Plans US launch before the 2023/24 RSV season. Read More
(Alliance News) - Stocks in London were higher at the close on Wednesday as investor waited with bated breath for the US Federal Reserve's next interest rate decision. Read More
(Alliance News) - GSK PLC on Thursday said its respiratory syncytial virus vaccine candidate has gained positive opinion from the European Medicines Agency body. Read More
Schroders PLC - London-based investment manager - Hires Richard Oldfield to succeed Richard Keers as chief financial officer and an executive director. Oldfield currently is vice chair & global markets leader at accountants PricewaterhouseCoopers. Oldfield will join Schroders on October 2, and Keers will depart on December 31 after 10 years with the company. At Schroders, Oldfield will be responsible for "firm-wide operations" and for "financial management, risk management, technology, capital and treasury". Read More
(Alliance News) - European equities closed lower on Wednesday, with lingering banking sector worries hurting sentiment, while tech stocks outperformed wider markets in New York after well-received earnings overnight. Read More
(Alliance News) - Derren Nathan, head of equity research at Hargreaves Lansdown, said that GSK PLC got off to a "healthy start" to 2023, despite the pharmaceutical firm reporting a slip in first quarter sales. Read More
(Alliance News) - Brentford, London-based GSK PLC on Wednesday reported a slip in quarterly sales, but confirmed its 2023 guidance. Read More
(Alliance News) - Stocks in London were set to open lower on Wednesday as worries about the US banking sector returned. Read More
(Alliance News) - GSK PLC on Tuesday said the European Medicines Agency has validated its marketing authorisation application for its dostarlimab drug, marketed as Jemperli. Read More
(Alliance News) - Haleon PLC's range of name-brand consumer products seem to be performing well in 2023 so far, despite elevated inflation making consumers increasingly cost-conscious. Read More
(Alliance News) - Hundreds of UK workers at pharmaceutical firm GSK PLC will stage a series of walkouts in May in a dispute over pay. Read More
(Alliance News) - GSK PLC on Tuesday announced it has agreed to acquire Quebec-based late-stage biopharmaceutical firm Bellus Health Inc for a total equity value of USD2.0 billion. Read More